A new vaccine allows pneumonia-causing bacteria to colonize inside the body, springing into action only if the bacteria pose a threat.
The breakthrough approach, coupled with the protein-based vaccine’s potential to counteract more than 90 strains of the bacteria, has the makings to override how vaccines have worked (destroying bacteria before colonization) since the days of Louis Pasteur.
Moreover, it offers what could be the most direct and broad response to pneumonia – the leading cause of death of children worldwide under the age of 5, according to the World Health Organization – as well as meningitis, sepsis and other serious infections caused by Streptococcus pneumoniae, a bacteria more commonly known as pneumococcus.
“These are very serious illnesses that we haven’t been able to completely suppress. The vaccine we’re developing could finally get that job done,” says Blaine A. Pfeifer, PhD, an associate professor of chemical and biological engineering at the University at Buffalo School of Engineering and Applied Sciences.
The work is described in a study, published today (June 6) in the Proceedings of the National Academy of Sciences, led by Pfeifer and UB alumnus Charles H. Jones, PhD, who is leading efforts to commercialize the vaccine at Buffalo-based startup Abcombi Biosciences.
“With conventional vaccines, the approach has been: ‘What bacteria do we want to target and how,’” says Jones, CEO and founder of Abcombi, and a former student of Pfeifer’s. “Our strategy is to shift the paradigm to which diseases do we want to prevent.”
Bacteria is still deadly
To treat and prevent illnesses caused by pneumococcus, doctors almost exclusively relied on penicillin and other common antibiotics. While still used, the effectiveness of these drugs has been waning for decades due to bacteria developing antibiotic resistance.
The situation led pharmaceutical companies to develop preventative vaccines, which have reduced deaths and illnesses, especially in developed nations. But pneumococcus remains a serious problem.
Pneumonia killed 1.3 million people worldwide in 2011, with the majority of deaths in Sub-Saharan Africa and South Asia. In the United States alone, pneumonia, meningitis and sepsis cause tens of thousands of deaths each year, according to the National Foundation for Infectious Diseases.
One reason for this is that current vaccines target only a small percentage – those known to cause the most severe infections – of the more than 90 strains of pneumococcus. These vaccines, which identify pneumococcus by a sugar coating that surround the bacteria, are 56 to 88 percent effective.
A new type of vaccine
The UB and Abcombi-led team took a different approach. Its vaccine identifies strains by proteins attached to the surface of pneumococcus. Laboratory tests show the vaccine can defend against more than 12 strains and that it’s 100 percent effective at promoting the appropriate immune response.
Computer simulations indicate the vaccine would be effective against all strains but additional tests are needed to confirm that.
“It’s like the arcade game Whac-A-Mole. Think of the mallet as a traditional vaccine. It can’t stop all the moles, or in our case, all the strains of bacteria at once,” Jones says. “But our vaccine does just that. It’s like a mallet with 90 heads that strikes all the moles simultaneously.”
The ability to fight numerous strains is important, Jones says, because developing new versions of existing vaccines is both costly and time-consuming.
The new vaccine also differs from what’s on the market by its response to the bacteria.
Current vaccines teach the immune system to indiscriminately destroy bacteria and other pathogens, thus preventing colonization. The approach works, but there is growing concern that it can create space within the body for new and potentially more harmful alternatives to establish residence – similar to antibiotic resistance resulting in new and more potent pathogens.
The new vaccine allows bacteria to exist as long as it causes no harm to body. It instructs the immune system to attack only when the surface proteins, mentioned above, break free of the bacterial coating.
“That’s the signal that this bacteria is becoming a troublemaker, that’s its threatening the body and that it’s necessary to fight back,” Pfeifer says.
Having proved the vaccine’s effectiveness in animals, Abcombi is now leading efforts to conduct human trials.
The Latest on: New vaccine
via Google News
The Latest on: New vaccine
- People line up for COVID-19 vaccine at Nassau Community College amid omicron concernson December 4, 2021 at 2:22 pm
People lined up at Nassau Community College Saturday to get vaccinated against COVID-19 after Gov. Kathy Hochul announced that there are now eight active cases of the omicron variant in the state.
- Judge denies request by L.A. firefighters union for injunction to block vaccine mandate enforcementon December 4, 2021 at 12:50 pm
The enforcement of a mandate requiring Los Angeles Fire Department employees to get vaccinated cannot be delayed, a judge ruled Friday.
- Omicron Variant That May Evade Vaccines Found in These U.S. Stateson December 4, 2021 at 11:39 am
The Omicron variant, which experts worry could render vaccines less effective, has now been identified in 11 states in the United States. Omicron was first identified in South Africa on November 24 ...
- U.S. drugstores squeezed by vaccine demand, staff shortageson December 4, 2021 at 11:15 am
A rush of vaccine-seeking customers and staff shortages are squeezing drugstores around the U.S., leading to frazzled workers and temporary pharmacy closures.
- Omicron variant FAQ: 8 key things to know about the new COVID strainon December 4, 2021 at 11:06 am
Bit by bit we're getting a clearer picture of the new omicron variant of COVID-19. Stay on top of the latest guidance here.
- Omg, Omicron! Why it’s too soon to panic about COVID vaccines and new varianton December 4, 2021 at 11:01 am
The reason Omicron has caused global alarm is due to the number of new mutations throughout the genome of SARS-CoV-2, the virus that causes COVID ...
- New Covid-19 Vaccine, Myocarditis Claims From Questionable Abstract In American Heart Association Journalon December 4, 2021 at 10:16 am
A research abstract that was published on November 8 in the medical journal Circulation has gotten a fair amount of circulation on social media. The abstract made a pretty dramatic claim: “mRNA vacs ...
- Frazzled workers, temporary closures: How staff shortages and vaccine demand are squeezing US pharmacieson December 4, 2021 at 10:10 am
Drugstores are normally busy this time of year, but now pharmacists are doling out a growing number of COVID-19 shots and giving coronavirus tests.
- Man Tries To Dodge COVID Vaccine Using Fake Armon December 4, 2021 at 8:59 am
A dentist in Italy who needed a vaccine certificate offered up a "rubber foam" arm in an attempt to evade the actual shot.
- Pfizer said it expects to have more data by end of year on whether COVID-19 vaccine can be administered to children under 5on December 4, 2021 at 7:40 am
Dr. Anthony Fauci has predicted that parents won't have to wait much longer for kids under 5 to receive a vaccine.
via Bing News